Harvard Bioscience (HBIO) Invested Capital (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Invested Capital data on file, last reported at $10.0 million in Q1 2026.

• Quarterly Invested Capital fell 80.22% year-over-year to $10.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.0 million (down 80.22% YoY) and the FY2025 annual result came in at $13.7 million, down 86.31% from the prior year.
• Invested Capital declined to $10.0 million in Q1 2026 per HBIO's latest filing, from $13.7 million in the prior quarter.
• Across five years, Invested Capital topped out at $126.0 million in Q2 2022 and bottomed at $10.0 million in Q1 2026.
• The 5-year median for Invested Capital is $104.4 million (2024), against an average of $90.2 million.
• The widest annual swing landed in 2022, when Invested Capital grew 3.86%; it then sank 86.31% in 2025.
• Tracing HBIO's Invested Capital over 5 years: stood at $119.0 million in 2022, then decreased by 7.9% to $109.6 million in 2023, then fell by 8.52% to $100.3 million in 2024, then slumped by 86.31% to $13.7 million in 2025, then retreated by 26.85% to $10.0 million in 2026.
• Per Business Quant, the three latest HBIO Invested Capital figures stand at $10.0 million (Q1 2026), $13.7 million (Q4 2025), and $48.0 million (Q3 2025).

Peer Comparison